BioVie Inc (BIVI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$1.97-4.83%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Intact: The reason to own it still holds.
BioVie is a clinical-stage biotech with a $14.7M market cap. It recently raised capital through a $5.62M offering. The company has stable management and no recent market stress. This funding supports its drug development pipeline.
BioVie is loss-making with no revenue or EPS estimates for 2027. It lacks analyst coverage and guidance. The biotech sector median PE is 21.7, but BioVie has no earnings. The company faces high risk and uncertain prospects.
No clear market consensus or price targets exist due to lack of analyst coverage. The stock price reflects speculative value on early-stage biotech potential rather than fundamentals.
Breaks if: capital raises fall below $5M or fail to close within 12 months
Breaks if: major management departures or instability within 12 months
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. BIVI is focused on advancing its clinical development for Parkinson's disease, but it is currently loss-making and faces elevated risks.
The market appears to be pricing in a challenging outlook, given the company's loss-making status and recent financial performance that lags behind its peers. There is a low confidence level in the current valuation, reflecting the uncertainty surrounding future earnings.
Management has recently highlighted progress in clinical trials for bezisterim, which may support future growth. However, the company has a high probability of missing earnings expectations, which adds to the uncertainty in the near term.
The thesis hinges on the performance of sector bellwethers like VRTX, REGN, and ARGX, as their results could influence BIVI's trajectory. Additionally, the success of bezisterim in clinical trials and management's ability to address unmet clinical needs will be critical.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: no revenue or clinical progress by FY27
In the next 1 to 3 years, BIVI's outlook will depend on clinical trial results and sector performance, with significant risks present. Not investment advice.